Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo de Fase II em Doentes Adultos e Jovens Adultos com DSRCT (ISG-TULIPS)

2 de novembro de 2026 atualizado por: Italian Sarcoma Group

Estudo de Fase II com Lurbinectedina e Irinotecano em Doentes Adultos e Jovens Adultos com Tumor Desmoplásico de Células Redondas Pequenas (DSRCT) Avançado

Patients participating in this study have DSRCT that has spread locally or to other parts of the body and can no longer be surgically removed without causing significant harm.

Treatment will continue until the tumor progresses further, severe side effects occur, or either patient or investigator decision.

In addition, patients may participate in an optional biological study. The study will analyze the tumor's genes and the molecules related to them. By studying genes and their products, the investigators can better understand the behavior of the tumor and how the body responds to therapies.

Visão geral do estudo

Descrição detalhada

This is an Italian and Spanish multicentric, prospective, phase II single-arm, open-label, investigator-initiated clinical study that will be conducted within the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Groups (GEIS), aiming at exploring the activity of lurbinectedinin combination with irinotecan, until progression or unacceptable toxicity, in a population of =/>15 years old patients with histologically and molecularly confirmed (EWSR1-WT1 translocation positive), advanced (locally advanced or metastatic) DSRCT, from 2nd to 4th line, following progression to anthracycline-based chemotherapy.

The primary end-point of the study will be the overall response rate (ORR) by RECIST v1.1 in the study population. Secondary end-points will be PFS, DoR, OS, safety and changes in QoL.

Patients will be evaluated for the primary end-point if have completed at least one cycle of lurbinectedin and irinotecan and have at least one post-baseline radiologic disease assessment. Patients with documented early progression disease (PD) or who die due to PD before the first scheduled tumor assessment will also be included in the analysis.

Patients will be followed for follow up visits every 6 months for 2 years.

Tipo de estudo

Intervencional

Inscrição (Estimado)

20

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

      • Barcelona, Espanha, 08035
        • Ainda não está recrutando
        • Vall d'Hebron University Hospital
        • Contato:
        • Investigador principal:
          • Claudia Valverde
      • Madrid, Espanha, 28040
        • Recrutamento
        • Hospital Universitario Fundación Jiménez Díaz
        • Contato:
        • Investigador principal:
          • Nadia Hindi
      • Madrid, Espanha, 28040
        • Ainda não está recrutando
        • Hospital Clinico Universitario San Carlos
        • Investigador principal:
          • Gloria Marquina
        • Contato:
      • Murcia, Espanha, 30120
        • Ainda não está recrutando
        • Virgen of Arrixaca University Clinical Hospital
        • Investigador principal:
          • Jose Luis Alonso
        • Contato:
          • Jose Luis Alonso, MD
      • Seville, Espanha, 41013
        • Ainda não está recrutando
        • Hospital Univ. Virgen del Rocío
        • Contato:
          • Irene Carrasco Garcìa, MD
        • Investigador principal:
          • Irene Carrasco Garcìa
      • Zaragoza, Espanha, 50009
        • Ainda não está recrutando
        • Hospital Univ. Miguel Servet
        • Contato:
          • Javier Martinez, MD
        • Investigador principal:
          • Javier Martinez
      • Milan, Itália, 20133
      • Padova, Itália, 35128
        • Recrutamento
        • IOV Istituto Oncologico Veneto IRCCS
        • Investigador principal:
          • Antonella Brunello
        • Contato:
      • Prato, Itália, 59100
      • Roma, Itália, 00128
        • Recrutamento
        • Fondazione Policlinico Universitario Campus Bio-Medico
        • Investigador principal:
          • Alessandro Mazzocca
        • Contato:
    • Torino
      • Candiolo, Torino, Itália, 10060
        • Recrutamento
        • Fondazione del Piemonte per l'Oncologia IRCCS
        • Contato:
        • Investigador principal:
          • Sandra Aliberti

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

15 anos e mais velhos (Filho, Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Histological centrally confirmed diagnosis of DSRCT with the documented presence of EWSR1-WT1 translocation.

  2. Age ≥ 15 years.

  3. Locally advanced (i.e. radical surgical resection of local disease unfeasible or surgery declined by the patient or surgery deemed to become less demolitive and / or easier after cytoreduction) and/or metastatic disease.

  4. Measurable disease by RECIST v1.1.

  5. Clinical or objective disease progression after the last administration of the last standard therapy, or have stopped standard therapy due to intolerability within 6 months from enrollment.

  6. At least one prior chemotherapy based on anthracycline (considering chemotherapy administered for primary tumour) and no more than 3 prior chemotherapy lines.

  7. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2.

  8. Adequate bone marrow, renal, hepatic, and metabolic function (assessed ≤ 7 days before inclusion in the trial), defined as the following:

    1. platelet count ≥ 100 × 109/L, hemoglobin ≥ 9.0 g/dL, white blood cells ≥ 3.0 × 109/L and absolute neutrophil count (ANC) ≥ 2.0 × 109/L,
    2. aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × the upper limit of normal (ULN), even in the presence of liver metastases,
    3. total bilirubin ≤ 1.5 × ULN or direct bilirubin ≤ ULN,
    4. International Normalized Ratio (INR) < 1.5 (except if patient is on oral anticoagulation therapy),
    5. calculated creatinine clearance (CrCL) ≥ 30 mL/minute (using Cockcroft-Gault formula),
    6. creatine phosphokinase (CPK) ≤ 2.5 × ULN,
    7. albumin ≥ 3.0 g/dL.
  9. Cardiac ejection fraction ≥50% as measured by echocardiogram.

  10. Recovery to grade ≤ 1 or to baseline from any adverse event (AE) derived from previous treatment (excluding alopecia and/or cutaneous toxicity and/or fatigue grade ≤ 2).

  11. No history of arterial and/or venous thromboembolic event within the previous 12 months.

  12. Females of childbearing potential must have a negative pregnancy test (preferable by serum or, if serum test unavailable, urine beta-HCG) within 7 days before treatment start.

  13. Post-menopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential.

  14. Male and female patients of reproductive potential must agree to employ a highly effective method of birth control (Acceptable methods of contraception are described in Appendix 5) throughout the study and thereafter, at the end of study treatment, and for at least 7 months from the patient's last lurbinectedin administration in female patients of childbearing potential and for at least 4 months in men in fertile age after the last lurbinectedin administration.

  15. The patient or legal representative must be able to read and understand the informed consent form (ICF) and must have been willing to give written informed consent and any locally required authorisation before any study-specific procedures, including screening evaluations, sampling, and analyses.

Exclusion Criteria:

  1. Prior treatment with lurbinectedin or trabectedin, Ecubectedin (PM 14) or PM54.
  2. Known hypersensitivity to irinotecan or lurbinectedin or any of their components of the drugs products (excipients).
  3. Other primary malignancy with <5 years clinically assessed disease free interval, except basal cell skin cancer, cervical carcinoma in situ or other neoplasm judged to entail a low risk of relapse.
  4. History or presence of unstable angina, myocardial infarction, or clinically significant valvular heart disease within 12 months of the study.
  5. Grade III/IV cardiac problems as defined by the New York Heart Association Criteria (i.e. congestive heart failure, myocardial infarction within 12 months of study).
  6. Symptomatic arrhythmia or any uncontrolled arrhythmia requiring ongoing treatment within 12 months of study.
  7. Myopathy or any clinical situation that causes significant and persistent elevation of CPK (> 2.5 × ULN in two different determinations performed one week apart).
  8. Severe and/or uncontrolled medical disease (i.e. uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).
  9. Known active brain metastasis.
  10. Known chronic liver disease (i.e. chronic active hepatitis and cirrhosis).
  11. Diagnosis of human deficiency virus (HIV), hepatitis C virus (HCV) infection or active hepatitis B (to be excluded during the screening period).
  12. Any past or present chronic inflammatory colon and/or liver disease, past intestinal obstruction, pseudo or sub-occlusion or paralysis.
  13. Evident symptomatic pulmonary fibrosis or interstitial pneumonitis, pleural or cardiac effusion rapidly increasing and/or necessitating prompt local treatment within seven days.
  14. Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study.
  15. Known active COVID-19 disease (this includes positive test for SARS-CoV-2 in nasopharyngeal/oropharyngeal swabs or nasal swabs by PCR).
  16. Prior bone marrow and/or stem cell transplantation, and allogenic transplant.
  17. Last dose of systemic cytotoxic therapy or investigational therapy within 21 days from enrollment.
  18. Prior treatment with any form of radiation therapy within 14 days from enrollment.
  19. Major surgery within 3 weeks prior to study entry and minor surgery within 1 week prior to study entry.
  20. Use of strong inducers of CYP3A activity within two weeks prior to the first infusion of lurbinectedin (Appendix 6).
  21. Expected limitation of the patient's ability to comply with the treatment or follow-up protocol.
  22. Subjects who have current active hepatic or biliary disease (with exception of patients with asymptomatic gallstones, liver metastasis or stable chronic liver disease per Investigator assessment).
  23. Subjects who have known Gilbert's syndrome.
  24. Patient has received a live or liver attenuated vaccines within 30 days before the first dose of study intervention. Killed vaccines are allowed.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Lurbinectedine and Irinotecan

lurbinectedin in combination with intravenous irinotecan administered until progression or unacceptable toxicity, in a population of =/>15 years old patients with histologically and molecularly confirmed (EWSR1-WT1 translocation positive), advanced (locally advanced or metastatic) DSRCT, from 2nd to 4th line, following progression to anthracycline-based chemotherapy.

Lurbinectedin and Irinotecan

Lurbinectedin and Irinotecan

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Overall tumour Response Rate (ORR), according to RECIST v 1.1
Prazo: Week 6, week 12, week 18, week 30, week 42, week 54, week 66, week 78, week 90, week 102 and until progression

Overall tumour Response Rate (ORR), according to RECIST v 1.1

Week 6, week 12, week 18, week 30, week 42, week 54, week 66, week 78, week 90, week 102 and until progression

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Overall Survival (OS)
Prazo: From date of study therapy start until the date of death from any cause, assessed up to 60 months

Overall Survival (OS)

From date of study therapy start until the date of death from any cause, assessed up to 60 months
Progression Free Survival (PFS)
Prazo: From date of study therapy start until first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

Progression Free Survival (PFS)

From date of study therapy start until first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
Duration of Response (DoR)
Prazo: From date of study therapy start until first documented assessment without progression or date of death from any cause, whichever came first, assessed up to 60 months

Duration of Response (DoR)

From date of study therapy start until first documented assessment without progression or date of death from any cause, whichever came first, assessed up to 60 months
Adverse events and Serious adverse event (according to CTC-AE v.5)
Prazo: After initiation of study treatments(s), all adverse events will be reported until 30 days after the final dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurs first.

Adverse events and Serious adverse event (according to CTC-AE v.5)

After initiation of study treatments(s), all adverse events will be reported until 30 days after the final dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurs first.
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Prazo: Screening, cycle1 day1 (each cycle is 21 days), cycle2 day1, End Of Treatment visit (performed 30 days after the last study drug administration), at follow-up visits performed at months 6, 12, 18 and 24 after the last study drug administration

The EORTC QLQ-C30 is a validated 30-item questionnaire assessing health-related quality of life in cancer patients. Scores are linearly transformed to a 0 to 100 scale.

For the Global Health Status/Quality of Life and functional scales (physical, role, emotional, cognitive, and social functioning), higher scores indicate better quality of life or functioning.

For the symptom scales and single-item symptom measures, higher scores indicate greater symptom severity (worse outcome).

Screening, cycle1 day1 (each cycle is 21 days), cycle2 day1, End Of Treatment visit (performed 30 days after the last study drug administration), at follow-up visits performed at months 6, 12, 18 and 24 after the last study drug administration
Brief Inventory Pain questionnaire
Prazo: Screening, cycle1 day1 (each cycle is 21 days), cycle2 day1, End Of Treatment visit (performed 30 days after the last study drug administration), at follow-up visits performed at months 6, 12, 18 and 24 after the last study drug administration

Brief Inventory Pain questionnaire

Screening, cycle1 day1 (each cycle is 21 days), cycle2 day1, End Of Treatment visit (performed 30 days after the last study drug administration), at follow-up visits performed at months 6, 12, 18 and 24 after the last study drug administration

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Silvia Stacchiotti, MD, Findazione IRCCS Istituto Nazionale Tumori Milano

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

21 de novembro de 2025

Conclusão Primária (Estimado)

1 de outubro de 2030

Conclusão do estudo (Estimado)

1 de outubro de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

17 de novembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de janeiro de 2026

Primeira postagem (Real)

9 de janeiro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

3 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever